Production (Stage)
Ligand Pharmaceuticals Incorporated
LGND
$105.99
$1.811.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -42.45M | -31.09M | -7.17M | -51.91M | 86.14M |
| Total Depreciation and Amortization | 8.31M | 8.63M | 8.99M | 8.85M | 8.77M |
| Total Amortization of Deferred Charges | 707.00K | 743.00K | 707.00K | 600.00K | 562.00K |
| Total Other Non-Cash Items | 13.16M | 38.59M | 26.88M | 63.38M | -84.98M |
| Change in Net Operating Assets | -5.17M | 11.60M | 7.12M | -7.61M | 8.24M |
| Cash from Operations | -25.45M | 28.47M | 36.53M | 13.31M | 18.73M |
| Capital Expenditure | -214.00K | -712.00K | -596.00K | -408.00K | -105.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 5.11M | -37.91M | -45.91M | -54.35M | -3.67M |
| Cash from Investing | 4.89M | -38.62M | -46.51M | -54.76M | -3.78M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -7.00K | -6.00K | -10.00K | -4.00K | -5.00K |
| Issuance of Common Stock | 4.22M | 56.48M | 21.40M | 9.55M | 15.30M |
| Repurchase of Common Stock | -8.89M | -1.94M | -125.00K | 0.00 | -3.08M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -71.00K | -34.15M | 33.82M | -57.00K | -41.00K |
| Cash from Financing | -4.75M | 20.39M | 55.08M | 9.49M | 12.18M |
| Foreign Exchange rate Adjustments | 1.06M | -1.55M | 377.00K | -- | -- |
| Miscellaneous Cash Flow Adjustments | -78.00K | -- | -- | -- | -- |
| Net Change in Cash | -24.32M | 8.69M | 45.48M | -31.95M | 27.14M |